H.R. 1432 - Preserve Access to Affordable Generics Act
- Sponsor:
- Henry Waxman
- Summary:
- To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market. (by CRS)
- Status:
- The bill has been introduced.
Preserve Access to Affordable Generics Act
H.R. 1432 — 110th Congress (2007–2008)
- Summary
- To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market. (by CRS)
- Learn More
- At OpenCongress
- Title
- To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market.
- Other Titles
- Preserve Access to Affordable Generics Act
- Sponsor
- Henry Waxman
- Co-Sponsors
- Subjects
- Business
- Antitrust law
- Competition
- Drug industry
- Generic drugs
- Intellectual property
- Marketing
- Medical care
- Medicine
- Patent infringement
- Pharmaceutical research
- Restrictive trade practices
- Science policy
- Related Bills
- Major Actions
Introduced 3/09/2007 Referred to Committee - Bill History
-
There have been no votes on this bill.
Action Date Description Introduced 3/09/2007 3/09/2007 Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. 3/09/2007 Referred to House Energy and Commerce 3/09/2007 Referred to House Judiciary 3/12/2007 Referred to the Subcommittee on Commerce, Trade and Consumer Protection. Number Sponsor Date Offered Status
MapLight did not identify any interest groups that took a position on this vote.
You may be able to explore campaign contributions data if you add interest groups.
Help your colleagues by suggesting an organization that took a position on this vote.
Contributions data source: OpenSecrets.org
